Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-MPV-radiotherapy-high-dose cytarabine with geriatric assessment-based dose modification in elderly primary CNS lymphoma
jRCTs061180093Phase 2Active, not recruiting
- Sponsor
- Hiroshima University
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, methotrexate, procarbazine, vincristine and cytarabine in primary central nervous system lymphoma (PCNSL), sponsored by Hiroshima University. Primary endpoint: Overall survival. Started Jul 2019; status: active, not recruiting.
02
Drugs
rituximabmethotrexateprocarbazinevincristinecytarabine
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on jRCTs061180093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061180093.